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Objectives The aim of this systematic review was to study the benefits and risks of beta-adrenergic antagonists (beta-
blockers) in patients with chronic kidney disease (CKD).
Background There is an excess burden of cardiovascular disease and death in people with CKD. Despite their potential bene-
fits, the effects of beta-blockers in this population are uncertain.
Methods CENTRAL (Cochrane Central Register of Controlled Trials), Medline (Medical Literature Analysis and Retrieval
System Online), and Embase (Excerpta Medical Database) were searched for randomized controlled trials with at
least 3 months of follow-up in patients with CKD stages 3 to 5 that reported mortality outcomes. Summary esti-
mates of effect were obtained using a random effects model.
Results Eight trials met criteria for review: 6 placebo-controlled trials involving 5,972 participants with chronic sys-
tolic heart failure and 2 angiotensin-converting enzyme inhibitor–comparator trials involving 977 partici-
pants not known to have heart failure. In CKD patients with heart failure, compared with placebo, beta-
blocker treatment reduced the risk of all-cause (risk ratio [RR]: 0.72, 95% confidence interval [CI]: 0.64 to
0.80) and cardiovascular mortality (RR: 0.66, 95% CI: 0.49 to 0.89), but increased the risk of bradycardia
(RR: 4.92, 95% CI: 3.20 to 7.55) and hypotension (RR: 5.08, 95% CI: 3.48 to 7.41). Quantitative meta-
analysis was not performed for the non–heart failure studies due to substantial clinical diversity or lack of
informative data.
Conclusions Treatment with beta-blockers improved all-cause mortality in patients with CKD and chronic systolic heart fail-
ure. There is insufficient evidence to conclude whether people with CKD who are not known to have heart failure
derive benefit from beta-blockers. (J Am Coll Cardiol 2011;58:1152–61) © 2011 by the American College
of Cardiology Foundation
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September 6, 2011:1152–61 Beta-Blockers in Chronic Kidney DiseaseChronic kidney disease (CKD), defined as an estimated
glomerular filtration rate (eGFR) reduced to 60 ml/min/
1.73 m2 or excess proteinuria (250 mg/day or urine
lbumin-creatinine ratio 30 mg/g), is a major public
ealth problem affecting 8% to 12% of adults in industrial-
zed countries (1,2). Compared with the general population,
See page 1162
people with CKD, including those receiving dialysis, are at
greater risk of death (3–5). A cardiac cause accounts for 35%
to 40% of all deaths in patients with end-stage renal disease
on dialysis (6–8). In CKD patients who are not yet on
dialysis (nondialysis CKD patients), the risk of having a
cardiovascular event is inversely proportional to eGFR
(3,4,9–12). Results of a collaborative meta-analysis of gen-
eral population cohorts consisting of more than 1.2 million
people showed that eGFR 60 ml/min/1.73 m2 was an
independent predictor of all-cause and cardiovascular mor-
tality (13). Furthermore, there was an exponential increase
in the risk of death at lower eGFR levels.
Beta-adrenergic receptor antagonists (“beta-blockers”)
reduce mortality in patients following myocardial infarc-
tion and in patients with chronic systolic heart failure
(14,15). Evidence-based treatment guidelines recom-
mend their use in such patients unless contraindicated or
not tolerated (16,17). However, randomized controlled
trials (RCTs) providing this evidence have generally
excluded individuals with CKD, including end-stage
renal disease patients requiring dialysis (18,19). Ischemic
heart disease, congestive heart failure, arrhythmias, left
ventricular hypertrophy, and increased sympathetic ner-
vous system activity are highly prevalent in people with
advanced CKD, and this population could theoretically
derive large benefits from beta-blockers (7,8,20 –25).
Observational studies in patients with CKD have dem-
onstrated better survival and cardiovascular outcomes in
those treated with beta-blockers (26 –28). Despite this,
the use of beta-blockers in patients receiving dialysis
varies considerably, ranging from as few as 10% of
patients in Japan to approximately 60% in the United
States (29,30). In a study of nondialysis CKD patients
who had a myocardial infarction, the frequency of beta-
blocker use diminished as eGFR declined (3). In the
United States, 61% and 73% of all dialysis patients with
congestive heart failure and acute myocardial infarction,
respectively, were prescribed beta-blockers (30). The
variable rates of utilization of beta-blockers in dialysis
patients may be due to uncertainty regarding potential
benefits in this population, as well as the possibility of
hemodynamic side effects in patients subjected to wide
fluctuations in extracellular fluid volume. Several inves-
tigators have called for an increased use of beta-blockers
in dialysis patients while awaiting RCTs (31–34). iTherefore, the aim of this sys-
tematic review was to determine
the effects of beta-blockers on
clinical endpoints in patients
with CKD stages 3 to 5 includ-
ing those on dialysis.
Methods
A systematic review was under-
taken in accordance with the
PRISMA (Preferred Reporting
Items for Systematic Reviews
and Meta-Analyses) Statement
(35).
Search strategy, study selection,
and data extraction. Studies were eligible for inclusion if
they: 1) were randomized controlled trials; 2) included
participants with CKD stages 3 to 5 (eGFR 60 ml/min/
1.73 m2), including those on dialysis therapy, who were
andomized to an oral beta-blocking agent compared with
lacebo, a cardiovascular agent of another class, or no
reatment; 3) followed patients for at least 3 months
ost-randomization; and 4) reported mortality outcomes.
rials performed in kidney transplant patients were excluded.
Relevant studies were identified through electronic
earches of Medline (Medical Literature Analysis and Re-
rieval System Online) via Ovid (from inception to October
010), Embase (Excerpta Medical Database) (from incep-
ion to October 2010), and the CENTRAL (Cochrane
entral Register of Controlled Trials) (Issue 4, 2010)
ithout any language restriction. In addition, reference lists
f relevant review articles, systematic reviews, treatment
uidelines, textbook chapters, conference proceedings, and
nline trial registries were searched. Missing, incomplete, or
npublished data from clinical trials were requested from
he respective investigators/authors by e-mail. (See the
nline Appendix for complete search strategy.)
The following data were extracted using a standardized
orm: patient demographic details, study design and con-
uct, rates of outcome events, and adverse events. The
ethodological quality of each included study was assessed
sing the risk of bias assessment tool developed by the
ochrane Bias Methods Group (36). The following 6 items
ere assessed: 1) random sequence generation; 2) allocation
oncealment; 3) blinding; 4) incomplete outcome data;
) selective outcome reporting; and 6) any other bias (e.g.,
nsufficient rationale, study design).
utcomes assessed. The primary outcome assessed in this
eta-analysis was all-cause mortality. In addition, all other
eported clinical outcomes such as cardiovascular mortality,
udden death, all-cause hospitalization, hospitalization for
orsening of heart failure, and adverse events were assessed.
tatistical analysis. For dichotomous outcomes, the results
ere expressed as risk ratios (RRs) with 95% confidence
Abbreviations
and Acronyms
CI  confidence interval(s)
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
GFR  glomerular filtration
rate
LVEF  left ventricular
ejection fraction
RCT  randomized
controlled trial
RR  risk rationtervals (CIs). Summary estimates were obtained by ran-
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Beta-Blockers in Chronic Kidney Disease September 6, 2011:1152–61dom effects model using the DerSimonian and Laird
method (37). Heterogeneity across the studies was esti-
mated using the I-square test (38). I-square values of 25%,
50%, and 75% correspond to low, moderate, and high levels
of heterogeneity (39). Meta-analysis results were reported
only if the I-square value was lower than 75%. We analyzed
trials that only included participants with “heart failure”
separately to those with a broader range of participants
(“non–heart failure” studies) because there were substantial
differences in cardiovascular morbidity, comparator, and
duration of follow-up. If sufficient data were available,
subgroup analysis was performed according to severity of
kidney disease (nondialysis CKD and end-stage renal dis-
ease requiring dialysis). The statistical analyses were done
with Stata/SE (version 10.1, Stata Corp., College Station,
Texas).
Results
Selection and description of studies. Nine reports of 8
trials involving 6,949 patients were included in the system-
atic review (Fig. 1). Six trials were performed in 5,972
patients with chronic systolic heart failure (40–44). Data
from 2 of these trials were obtained from a previously
published patient-level meta-analysis (44). Data on the
Figure 1 PRISMA Flow Diagram Showing Selection of Studies
Eight trials were included in the systematic review. Of these, 6 trials involving chro
CKD  chronic kidney disease; PRISMA  Preferred Reporting Items for Systematnumber of events in the individual trial arms were not
available in 1 report (43) and, hence, were extracted from
the previous publication of the same trial (45). The remain-
ing 2 trials were conducted in 977 patients without heart
failure (46,47) (Table 1). One additional trial included
patients receiving dialysis and reported clinical endpoints in
abstract form (48), but we were unable to obtain the
necessary data required for inclusion.
Patients undergoing dialysis were included in only 1 of 6
chronic systolic heart failure studies (114 patients, all on
hemodialysis) (40). The remaining 5 trials were post hoc
analyses reporting on the subgroup of nondialysis CKD
patients within a larger study evaluating beta-blockers in
patients with chronic systolic heart failure (41–44). One of
these trials was restricted to elderly patients (age 70 years)
(41). The major distinction from the non–heart failure
studies was that all 6 trials compared a beta-blocker with a
placebo.
None of the 2 non–heart failure studies included dialysis
patients (Table 1) (46,47). A beta-blocker was used as an
active comparator to an angiotensin-converting enzyme
inhibitor in both of these trials, which had a primary
objective to study the effect of an angiotensin-converting
enzyme inhibitor on the progression of CKD (46,47).
stolic heart failure were included in the meta-analysis.
iews and Meta-Analyses; RCT  randomized controlled trial.nic sy
ic Rev
Characteristics of Included StudiesTable 1 Characteristics of Included Studies
First Author (Study)
(Ref. #) (Location) Inclusion Criteria n Active Treatment Control
LVEF (%),
Mean (SD)
GFR* or Type
of Dialysis,
Mean (SD) Follow-Up
Age (yrs),
Mean (SD)
Men
(%)
DM
(%)
MI
(%)
Concomitant
ACE Inhibition
(%)
Heart Failure Studies
Cice (39,48) ESRD 114 Carvedilol Placebo 26 (8) All HD 24 months 55 (7.6) 62 NR 70 100
(Italy) LVEF 35% (3.125–25 mg BD)
Symptomatic heart failure
(NYHA II–III)
Castagno GFR* 60 1,119 Bisoprolol (1.25–10
mg daily)
Placebo NR NR 1.3 yrs NR 66 14 70 95
(CIBIS-II) (42,44) LVEF 35% 450 (eGFR45) 28 (22.7, 32)† 38.4 (32.9, 42.1)† 71 (66, 75)†
(Multinational) Symptomatic heart failure
(NYHA III–IV)
669 (eGFR 45–60) 28 (23, 32)† 52.4 (48.9, 56.2)† 67 (61, 72)†
Ghali GFR* 60 1,469 Metoprolol CR/XL
(25–200 mg
daily)
Placebo 27 (7) 47.7 (9.5) 1 yr 68.1 (8.2) 68 29 55 95
(MERIT-HF) (41) LVEF 40% 493 (eGFR45) 27 (7) 36.6 (6.8)
(Multinational) Symptomatic heart failure
(NYHA II–IV)
976 (eGFR 45–60) 27 (7) 53.3 (4.4)
Cohen-Solal GFR* 60 704 Nebivolol Placebo 34.2 (12.1) 43.5 (8.9) 21 months 77.4 (5) 59 29 46 NR
(SENIORS) (40) Age 70 yrs (1.25–10 mg
daily)
(Multinational) Symptomatic heart failure
(NYHA II–IV) defined as
LVEF 35% or prior
hospitalization for heart
failure in the previous
year
Wali GFR* 60 2,566 CAPRICORN trial: Placebo 24 (8) 45.5 (9.6) 13 months 65.7 (10.5) 71 26 15 99
(Pooled data from
CAPRICORN and
COPERNICUS trials) (43)
CAPRICORN trial:
Symptomatic heart failure
Post-acute MI
2,364 (eGFR 30–60)
Carvedilol
(6.25–25 mg
BD)
COPERNICUS trial:
(Multinational) LVEF 40%
COPERNICUS trial:
Symptomatic or
asymptomatic
heart failure
LVEF 25%
197 (eGFR 15–30)
1 (eGFR15)
Carvedilol
(3.125–25 mg
BD)
NR
NR
NR
NR
NR
NR
Hannedouche (46)
(France)
Creatinine
200–400 mol/l
100 Acebutolol (400 mg
daily) or atenolol
(100 mg daily)
Enalapril (5–10 mg daily) NR Inulin clearance
25.7 (10.5)
3 yrs 51 (2.2) 53 Ex Ex NA
Wright
(AASK) (45)
GFR* 20 to 65
Hypertensive
877 Metoprolol (50–200
mg/day)
Ramipril (2.5–10 mg/day) NR 45.6 (13.1) 4.1 yrs 54.7 (10.6) 61 Ex NR NA
(United States)
*Expressed as ml/min/1.73 m2. †Expressed as median (interquartile range).
AASK  African American Study of Kidney Disease and Hypertension; ACE  angiotensin-converting enzyme; BD  twice daily; CAPRICORN  Carvedilol Post-Infarct Survival Controlled Evaluation; CIBIS-II  The Cardiac Insufficiency Bisoprolol Study II; COPERNICUS 
Effect of Carvedilol on Survival in Severe Chronic Heart Failure; DM  diabetes mellitus; eGFR  estimated glomerular filtration rate; ESRD  end-stage kidney disease; Ex  excluded; GFR  glomerular filtration rate; HD  hemodialysis; LVEF  left ventricular ejection
fraction; MERIT-HF Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; MImyocardial infarction; NA not applicable; NR not reported; NYHA New York Heart Association; SENIORS Study of Effects of Nebivolol Intervention on Outcomes
and Rehospitalization in Seniors With Heart Failure.
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Beta-Blockers in Chronic Kidney Disease September 6, 2011:1152–61Figure 2 summarizes the risk of bias assessment of the
ndividual studies. Allocation concealment was adequate in
nly 4 trials. The only trial involving dialysis patients with
eart failure was a double-blind protocol during the
nitial 12 months (40), but became an open-label protocol
fter 12 months, and the investigators reported mortality
fter the second 12-month period in a subsequent pub-
ication (49).
ffects of intervention. HEART FAILURE STUDIES. Com-
pared with placebo, treatment with beta-blockers reduced
the risk of all-cause mortality (6 trials; risk ratio [RR]: 0.72,
95% confidence interval [CI]: 0.64 to 0.80, p  0.001; test
for heterogeneity I-square  0%, p  0.601) (Fig. 3). The
p values testing for an interaction between CKD status and
the effect of beta-blockers on all-cause mortality were
nonsignificant in each of the 5 post-hoc CKD subgroup
analyses of larger trials, indicating that the treatment effect
was similar in CKD patients and those without CKD. Data
on cardiovascular mortality were reported from 4 trials (n 
3,384) with results that again favored beta-blockers (RR:
0.66, 95% CI: 0.49 to 0.89, p  0.006) (Fig. 4), although
moderate level heterogeneity was present (I-square 
64.2%, p  0.045).
Only 1 trial included dialysis patients (40), and the overall
results were not significantly changed by exclusion of this
study for mortality (RR: 0.72, 95% CI: 0.64 to 0.81, p 
0.001; test for heterogeneity: I-square  0%, p  0.435),
whereas the effects on cardiovascular mortality became more
Figure 2 Summary of Risk of Bias Assessment
The risk of bias assessment was performed using a tool developed by the Cochra
Blinding of outcome assessors was adequate in 5 trials.clearly beneficial and consistent (3,270 nondialysis patients; t3 trials; RR: 0.76, 95% CI: 0.64 to 0.90, p  0.001; test for
heterogeneity: I-square  0%, p  0.92).
The risk of sudden death was also reduced by beta-
blockers (4 trials; RR: 0.70, 95% CI: 0.55 to 0.89, p 
0.004; test for heterogeneity: I-square  0%, p  0.491)
(Online Fig. 1), whereas beta-blockers did not significantly
affect the risk of all-cause hospitalization (2 trials; RR: 0.75,
95% CI: 0.52 to 1.08, p  0.121; test for heterogeneity:
I-square  67.1%, p  0.050). Summary statistics for
hospitalization for worsening of heart failure are not re-
ported due to the presence of high-level heterogeneity (4
trials; I-square  82.5%, p  0.003).
NON–HEART FAILURE STUDIES. There were substantial dif-
erences in the baseline eGFR and blood pressure target
etween the 2 non–heart failure studies (46,47). Due to the
elatively larger sample size and number of mortality events,
he AASK (African American Study of Kidney Disease and
ypertension) trial (46) dominated the pooled estimates
ith a weighting of 96.3%. Therefore, a quantitative meta-
nalysis is not reported. Data on cardiovascular mortality
as only reported in 1 trial, so meta-analysis was not
ossible.
dverse effects. HEART FAILURE STUDIES. There was in-
dequate reporting of rates of study medication discontin-
ation due to adverse events in 3 trials (43,44). In the
emaining 3 trials, discontinuation of study medication in
he beta-blocker arm was comparable to the control arm (3
s Methods Group. Allocation concealment was adequate in 4 trials.ne Biarials RR: 1.17, 95% CI: 0.66 to 2.09, p  0.585; I-square 
1157JACC Vol. 58, No. 11, 2011 Badve et al.
September 6, 2011:1152–61 Beta-Blockers in Chronic Kidney Disease59.2%, p  0.086) (Fig. 5) (40–42). Compared with
placebo, treatment with beta-blockers was associated with
increased risk of bradycardia (4 trials; RR: 4.92, 95% CI:
3.20 to 7.55, p  0.001; I-square  0%, p  0.838) and
hypotension (4 trials; RR: 5.08, 95% CI: 3.48 to 7.41, p 
0.001; I-square  0%, p  0.941) (Fig. 5) (40,41,44). The
risk of hyperkalemia was similar in the 2 groups (3 trials;
RR: 2.16, 95% CI: 0.12 to 37.92, p  0.6; I-square  68.2%,
p  0.076) (Fig. 5) (40,44). Data on hyperglycemia was
reported in 1 trial only, hence a meta-analysis was not
possible.
Figure 3 Forest Plot: All-Cause Mortality
Compared with placebo, treatment with beta-blockers reduced the risk of all-cause
(44) includes pooled data from 2 trials—CAPRICORN (Carvedilol Post-Infarct Surviv
Chronic Heart Failure). CI  confidence interval; RR  risk ratio; SENIORS  Stud
With Heart Failure.
Figure 4 Forest Plot: Cardiovascular Mortality
Compared with placebo, treatment with beta-blockers reduced the risk of cardiova
heart failure. The report by Wali et al. (44) includes pooled data from 2 trials—CANON–HEART FAILURE STUDIES. Data on study medication
discontinuation due to adverse events (47) and hyperkalemia
(46) was reported in 1 trial each, so meta-analysis not possible
for these adverse events. Neither of the trials reported data on
bradycardia, hypotension, and hyperglycemia.
Discussion
This meta-analysis has demonstrated a 28% and 34%
relative reduction in all-cause and cardiovascular mortality,
respectively, with beta-blocker therapy in patients with
lity in chronic kidney disease patients with heart failure. The report by Wali et al.
trolled Evaluation) and COPERNICUS (Effect of Carvedilol on Survival in Severe
fects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors
mortality in chronic kidney disease patients with
RN and COPERNICUS. Abbreviations as in Figure 3.morta
al Con
y of Efscular
PRICO
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Beta-Blockers in Chronic Kidney Disease September 6, 2011:1152–61heart failure and CKD. Compared with placebo, there was
an increased risk of bradycardia and hypotension with
beta-blocker therapy in patients with heart failure. Only 1
trial assessing major clinical outcomes was designed to
include patients receiving dialysis. There is a paucity of data
on the effect of beta-blockers on patient-level clinical
outcomes in CKD patients without heart failure.
The excess burden of cardiovascular disease in patients
with CKD contributes to their poor survival (6–8). This is
likely partly due to traditional cardiovascular risk factors
such as hypertension, older age, dyslipidemia, and diabetes,
Figure 5 Forest Plot: Adverse Events
The risk of discontinuation of study medication due to adverse events was comparabl
data from 2 trials—CAPRICORN and COPERNICUS. MERIT-HF  Metoprolol CR/XL Raas these are highly prevalent in CKD patients (13,50). Inaddition, a combination of “nontraditional” risk factors
including anemia, hyperphosphatemia, chronic inflamma-
tion, oxidative stress, volume overload, medial vascular
calcification, and sympathetic nervous system overactivity
have been identified in this patient population. These risk
factors are also likely to contribute to elevated cardiovascular
risk (25,51). Randomized controlled trials assessing stan-
dard cardiovascular therapies in CKD patients have often
yielded disappointing results (52–54), possibly due to the
multifactorial nature of cardiovascular disease in CKD.
Given the high prevalence of heart failure (31% to 40%),
een beta-blockers and placebo. The report by Wali et al. (44) includes pooled
ed Intervention Trial in Chronic Heart Failure; other abbreviations as in Figure 3.e betw
ndomizischemic heart disease (33% to 39%), and arrhythmia (7% to
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September 6, 2011:1152–61 Beta-Blockers in Chronic Kidney Disease31%) in CKD patients (7,55), particular those requiring
dialysis (8), it is possible that CKD patients may derive
benefit from beta-blocker therapy that is similar to or
perhaps greater than that observed in other populations
(14,15). In this systematic review, data regarding nondialy-
sis CKD patients was obtained exclusively from post hoc
subgroup analyses of RCTs in patients with heart failure.
Although these studies were not specifically designed to
assess effects in people with CKD, the absence of an
interaction suggests that the benefits for all-cause and
cardiovascular mortality in nondialysis CKD patients are
similar to those in people who do not have CKD. Given that
atients with CKD have a higher frequency of cardiovascular
vents than patients with GFR 60 ml/min/1.73 m2 do, the
bsolute risk reduction with beta-blocker therapy should be
uch greater in this group.
This systematic review also highlights the absence of specific
vidence that beta-blockers reduce all-cause or cardiovascular
ortality in the individuals with CKD who do not have heart
ailure, particularly those undergoing dialysis. Such individuals
ay still have ischemic heart disease or arrhythmias and thus
ay derive benefit from beta-blockers. However, in patients
ndergoing hemodialysis, the hypotensive side effects of beta-
lockers may be exacerbated by marked fluctuations in extra-
ellular fluid volume. Only 1 trial reported clinical outcomes in
ialysis patients (40,49), and this included only 114 patients
ith symptomatic heart failure, contributing less than 15% of
he weight for the mortality outcome. The small sample size
nd the lack of blinding during the second 12-month period of
he study (when most events occurred) suggest that more
tudies are required.
tudy limitations. The limitations of this systematic re-
iew include the relatively small number of eligible studies,
he post hoc nature of analyses of the largest studies, the
ifficulties in defining “symptomatic” heart failure in pa-
ients with CKD, and the lack of systematic data on adverse
ffects. In this systematic review, data regarding nondialysis
KD patients was obtained exclusively from post hoc
ubgroup analyses of RCTs in patients with heart failure
hat defined CKD as an eGFR 60 ml/min/1.73 m2.
ecause patients with advanced CKD were excluded from
hese 5 heart failure studies, the majority of participants in
he CKD subgroups had relatively mild CKD. For example,
0% and 66% of participants from the CKD cohort of the
IBIS-II (Cardiac Insufficiency Bisoprolol Study II) (43)
nd MERIT-HF (Metoprolol CR/XL Randomized Interven-
ion Trial in Congestive Heart Failure) (42) studies, re-
pectively, had an eGFR between 45 and 60 ml/min/1.73 m2
at baseline. In the combined cohort of CAPRICORN
(Carvedilol Post-Infarct Survival Controlled Evaluation)
and COPERNICUS (Effect of Carvedilol on Survival in
Severe Chronic Heart Failure) studies, only 8% of all CKD
participants had eGFR 30 ml/min/1.73 m2 (44). There-
fore, the application of these results to patients with very
low levels of GFR (particularly 30 ml/min/1.73 m2) isimited by the smaller number of participants with such low
FR in these studies.
The definition of heart failure in terms of presence and
everity of symptoms was not uniform across the studies and
lmost all studies defined patients as “symptomatic” based on
he New York Heart Association functional classification of
ymptoms. Patients with CKD may report symptoms of heart
ailure, such as fatigue or dyspnea, even in the absence of heart
ailure. This was demonstrated in an analysis of 2,883 CKD
atients without heart failure, in which 25% of the cohort had
he modified Kansas City Cardiomyopathy Questionnaire
core75, a threshold suggestive of moderate burden of heart
ailure symptoms (56). However, as described in Table 1, all
tudies were uniformly composed of participants with low left
entricular ejection fraction (LVEF). Hence, the findings of
his systematic review apply to patients with CKD and heart
ailure with decreased LVEF, but not to patients with heart
ailure and preserved LVEF.
onclusions
his systematic review demonstrates that treatment with beta-
lockers decreased all-cause and cardiovascular mortality in
atients with CKD who have heart failure and low LVEF,
uggesting these individuals will obtain similar or greater
enefits than people with heart failure who do not have CKD.
The widespread use of beta-blockers to reduce cardiovas-
ular events and improve patient-level outcomes in patients
ith CKD who do not have heart failure or those with
ymptomatic heart failure and a normal LVEF cannot be
ecommended based on existing RCT evidence. The need
or adequately powered prospective RCTs assessing the
ffects of beta-blockers in a broader population of individ-
als with advanced CKD are supported by the demonstrated
ffects in people with CKD and heart failure, as well as by
he known cardiovascular pathophysiology that has been
escribed in this patient population. Such trials should
rovide a clear demonstration of the benefits and risks
ssociated with beta-blockers in patients with advanced
KD, particularly those receiving dialysis, and inform
otential use of a treatment to reduce the burden of death
nd disability suffered by this patient population.
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